Loading...
A major hurdle in the treatment of patients undergoing interventions for acute myocardial infarction (MI) is reperfusion injuries that occur with the return of vessel patency. Because inhibition of cyclophilin D reduces myocardial reperfusion injury, and cyclosporine is an inhibitor of cyclophilin D, European researchers conducted a multicenter, double-blind, industry-sponsored trial to investigate whether intravenous cyclosporine before percutaneous coronary intervention (PCI) might improve clinical outcomes. A total of 970 patients were randomized to receive cyclosporine or placebo. The two groups were similar at baseline, except the cyclosporine group had a lower proportion of smokers and a higher proportion of patients with multivessel …